Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clarithromycin, quantity: 500 mg - tablet, film coated - excipient ingredients: sorbic acid; hypromellose; hyprolose; sorbitan mono-oleate; vanillin; purified talc; silicon dioxide; stearic acid; quinoline yellow; propylene glycol; povidone; croscarmellose sodium; titanium dioxide; magnesium stearate; microcrystalline cellulose - klacid (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis; 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae; 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes; 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts of < 75 cells/cubic mm. (see precautions) disseminated infection due to mycobacterium avium complex should be excluded

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 500mg;  ; clarithromycin 500mg - film coated tablet - 500 mg - active: clarithromycin 500mg   excipient: croscarmellose sodium hydrated silica hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc quinoline yellow sorbic acid sorbitan oleate stearic acid titanium dioxide vanillin active: clarithromycin 500mg excipient: colloidal silicon dioxide croscarmellose sodium ethanol   hyprolose hypromellose magnesium stearate microcrystalline cellulose povidone propylene glycol purified talc purified water quinoline yellow sorbic acid sorbitan oleate stearic acid titanium dioxide vanillin - klacid tablets are indicated for treatment of infections caused by susceptible organisms. such infections include: · respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. · skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. · disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum, or mycobacterium kansasii. · prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. · clarithromycin in the presence of acid suppression is indicated for the treatment of duodenal ulcer and in reducing the rate of ulcer recurrence.

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - clarithromycin - tablet, film coated - 500 mg - clarithromycin 500 mg

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - clarithromycin - tablet, extended release - 500 mg - clarithromycin 500 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 500mg;   - powder for injection - 500 mg - active: clarithromycin 500mg   excipient: lactobionic acid sodium hydroxide - klacid i.v. is indicated whenever parenteral therapy is required for treatment of sensitive microorganisms in the following conditions: · upper respiratory tract infections. · lower respiratory tract infections. · skin and soft tissue infections.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbott laboratories (m) sdn. bhd. - clarithromycin -

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clarithromycin, quantity: 250 mg - tablet, film coated - excipient ingredients: sorbitan mono-oleate; pregelatinised maize starch; titanium dioxide; povidone; propylene glycol; hypromellose; silicon dioxide; sorbic acid; stearic acid; purified talc; hyprolose; quinoline yellow; vanillin; magnesium stearate; croscarmellose sodium; microcrystalline cellulose - klacid (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis; 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae; 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes; 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts of < 75 cells/cubic mm. (see precautions) disseminated infection due to mycobacterium avium complex should be excluded

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

city medical store - sole proprietorship l.l.c united arab emirates - 14's (14's blister x 1) - tablet - 500mg / tablet - infections-antibacterial

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - clarithromycin - tablet, film coated - 250 mg - clarithromycin 250 mg

Malta - English - Medicines Authority

abbott laboratories limited - clarithromycin 500 mg - modified-release tablet